Navigation Links
Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
Date:12/8/2009

DURHAM, N.C., Dec. 8 /PRNewswire/ -- Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension. The 12-week double-blind placebo controlled Phase 2 study investigated the effects of a novel low dose combination of amiloride HCl and spironolactone in obese adults with treatment-resistant hypertension and statistically met its primary endpoint. HTI was assisted in the successful execution of this trial by Cato Research Ltd., a global contract research and development organization ("CRO") that is affiliated with Cato BioVentures.

"HTI remained as virtual as possible during these challenging economic times and to do this we have strategically leveraged the clinical and regulatory expertise of Cato Research in reaching this important clinical milestone for the company," said Daniel Pharand, CEO of HTI.

Obese patients were enrolled in the study with all experiencing uncontrolled hypertension while taking 3 or more anti-hypertensive medications. After only one month of treatment with HTI101, there was a significant decrease in both systolic and diastolic blood pressure.

"We are pleased to see such a strong response of HTI-101 in this important patient population and feel that this could be a new tool for treating unabated hypertension," said Allen Cato, M.D., Ph.D., CEO of Cato Research Ltd.

HTI obtained the core technology through an exclusive patent a license agreement with the University of Alabama Research Foundation ("UABRF").

About Hemodynamic Therapeutics, Inc.

HTI was formed in 2004 as a majority-owned portfolio company of Cato BioVentures. Through its strategic development relationship with Cato BioVenture
'/>"/>

SOURCE Hemodynamic Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... TEL AVIV, Israel , May 23, 2013 ... of BrainTech Israel 2013 , Israel,s ... take place on October 14 th -15 th in ... 2 nd most innovative city in the world by ... the "Start-up Nation." BrainTech Israel 2013 will showcase ...
(Date:5/23/2013)... 23, 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... of David A. Ramsay ... recently Vice President, Corporate Development at Halozyme. ... "With his established financial management experience and his ... in our commercial group for the last four ...
(Date:5/23/2013)... 2013  Omeros Corporation (NASDAQ: OMER ... Application (IND) to evaluate OMS824 in Huntington,s disease ... Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 ... brain linked to a wide range of diseases ... OMS824 has shown promising results in animal models ...
Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4
... 2012 Sequenom, Inc. (NASDAQ: SQNM ) today announced ... other conditions, shares of its common stock in an underwritten public ... the offering may be completed, or as to the actual size ... is acting as sole book-running manager for the offering.  ...
... Gore & Associates is among just five workplaces to ... to Work For" since the rankings debuted three decades ... its workforce, earned the No. 38 spot on the ... (Photo:  http://photos.prnewswire.com/prnh/20120119/PH38553 ) Headquartered in Newark, Del., ...
Cached Medicine Technology:Sequenom Announces Proposed Public Offering of Common Stock 2W. L. Gore & Associates Named a Top U.S. Workplace 2
(Date:5/24/2013)... (PRWEB) May 24, 2013 Today marks ... all-new online Itinerary Builder. , The redesigned and ... create unique vacation itineraries on their computer or mobile ... , The interactive tool allows users to fill in ... browse through and select their choice of vacation packages, ...
(Date:5/24/2013)... American Fork, Utah (PRWEB) May 24, 2013 ... several years now and is excited to announce it’s new weight ... our product that we are offering our customers their money back ... says Dave Sherwin, CEO of HCG EZ Drops. “The HCG ... caloric intake; hence the 21 pounds in 21 days.” , The ...
(Date:5/23/2013)... Magnatag’s new magnetic 365-Day attendance and vacation monitor ... A Manufacturing Manager from Augusta GA told us, “We ... managers can check the board for themselves and we ... us and the board makes the record public so ... it has made a difference.” , “Our customers ...
(Date:5/23/2013)... FL (PRWEB) May 24, 2013 Internationally ... coaching educators in tennis for over 29 years, ... than 50 ATP & WTA players, Grand Slam winners, ... Italian Open Champions, 25 USTA National Junior Champions, 8 ... Junior Champions, including Sunshine Cup, Orange Bowl and Eddie ...
(Date:5/23/2013)... Orange County film studio and visual effects ... light leaks for Apple's Final Cut Pro X today. ... no longer have to worry about matching up the movement ... Said Christina Austin, CEO of Pixel Film Studios, "You have ... look." , ProLeak from Pixel Film Studios allows users to ...
Breaking Medicine News(10 mins):Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:New Attendance, Vacation and Training Tracker Board Reduces Employee Conflicts and Improves Attendance 2Health News:Internationally Respected Tennis Coach, Nick Saviano Opens Summer Training Registration 2Health News:Pixel Film Studios Releases ProLeak Light Leaks for Final Cut Pro X Today 2
... CLARA, Calif., FURSTENFELDBRUCK, Germany and YOKOHAMA CITY,Japan, ... real-time,compression technology company, Schleifring und Apparatebau GmbH, ... medical and defense markets,and Tokyo Electron Device ... boards, today announced an agreement for the ...
... the May/June issue of Health Affairs reports on the ... what one might expect from chronic disease management programs ... news for state Medicaid leaders struggling to meet the ... that some disease management efforts, even among relatively low-risk ...
... ... Quality Act (CEQA)., LOS ANGELES, May 12 ... planned expansion of its,Holy Cross Medical Center even as Superior Court ... was significantly flawed.,The groundbreaking ceremony held today appears to be an ...
... Denmark, May 12, Warner Chilcott and LEO ... and Drug Administration (FDA) has approved the,New ... 0.005% and,betamethasone dipropionate 0.064%) Topical Suspension. LEO ... the FDA in July 2007. Taclonex Scalp(R) ...
... Board:,NTRZ), a world leader in stabilized rice bran (SRB), ... first quarter ended,March 31, 2008. Consolidated net revenues rose ... compared to consolidated net revenues of $2.0,million for the ... due to a $860,000 increase in sales of products ...
... Baptist Health South,Florida Inc., a health care system ... $7,775,000 to settle claims that it violated the,False Claims ... by paying,excessive compensation to an oncology group that was ... the Department of Justice,announced today. The payments were made ...
Cached Medicine News:Health News:Samplify Systems Announces Availability of Compression for Computed Tomography; Integrated Slip-Ring Solution to be Jointly Developed with Schleifring und Apparatebau and Tokyo Electron Device Ltd. 2Health News:Samplify Systems Announces Availability of Compression for Computed Tomography; Integrated Slip-Ring Solution to be Jointly Developed with Schleifring und Apparatebau and Tokyo Electron Device Ltd. 3Health News:Samplify Systems Announces Availability of Compression for Computed Tomography; Integrated Slip-Ring Solution to be Jointly Developed with Schleifring und Apparatebau and Tokyo Electron Device Ltd. 4Health News:Chronic disease management: Does it improve health and save money? 2Health News:Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility 2Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 2Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 3Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 4Health News:NutraCea Announces First Quarter 2008 Financial Results 2Health News:NutraCea Announces First Quarter 2008 Financial Results 3Health News:NutraCea Announces First Quarter 2008 Financial Results 4Health News:NutraCea Announces First Quarter 2008 Financial Results 5Health News:NutraCea Announces First Quarter 2008 Financial Results 6Health News:Florida Hospital Group Pays U.S. $7,775,000 to Settle False Claims Act Allegations 2
... Triad Skull Clamp, compatible with the full ... of clamping force on all three skull ... the possibility of adjusting the force on ... be increased or decreased by adjusting the ...
A fully automated, benchtop instrument designed for high-volume urine testing, using Siemens' proven technology in dry-pad urine chemistry analysis....
... PocketChem UA is the first ... take up valuable lab bench space. ... the variability in results between operators ... on every run, corrects for ambient ...
... sensor catheters incorporate a lumen ... wire, or high-speed injection/guide wire. ... injection has two laterally opposed ... open-end pigtail extension for use ...
Medicine Products: